$0.65 Earnings Per Share Expected for DENTSPLY SIRONA Inc. (NASDAQ:XRAY) This Quarter

Wall Street brokerages predict that DENTSPLY SIRONA Inc. (NASDAQ:XRAY) will announce $0.65 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for DENTSPLY SIRONA’s earnings. The highest EPS estimate is $0.70 and the lowest is $0.59. DENTSPLY SIRONA reported earnings of $0.67 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 3%. The firm is expected to announce its next quarterly earnings report on Thursday, November 4th.

According to Zacks, analysts expect that DENTSPLY SIRONA will report full year earnings of $2.88 per share for the current financial year, with EPS estimates ranging from $2.86 to $2.90. For the next year, analysts anticipate that the firm will post earnings of $3.21 per share, with EPS estimates ranging from $3.09 to $3.33. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for DENTSPLY SIRONA.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, August 5th. The medical instruments supplier reported $0.71 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.06. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.01 billion. DENTSPLY SIRONA had a return on equity of 13.22% and a net margin of 9.06%. DENTSPLY SIRONA’s revenue was up 117.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.18) earnings per share.

Several equities research analysts recently weighed in on the company. HC Wainwright reduced their price target on DENTSPLY SIRONA from $72.00 to $66.00 and set a “neutral” rating on the stock in a research note on Monday, August 9th. Barrington Research raised their price objective on DENTSPLY SIRONA from $77.00 to $79.00 and gave the stock an “outperform” rating in a research note on Friday, August 6th. TheStreet upgraded DENTSPLY SIRONA from a “c+” rating to a “b” rating in a report on Thursday, August 5th. Finally, Zacks Investment Research raised DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a research note on Thursday, July 29th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $65.00.

Shares of XRAY stock opened at $59.28 on Wednesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.00 and a current ratio of 1.43. DENTSPLY SIRONA has a fifty-two week low of $41.52 and a fifty-two week high of $69.54. The stock has a 50 day moving average price of $61.76 and a two-hundred day moving average price of $63.77. The company has a market capitalization of $12.96 billion, a P/E ratio of 35.29, a PEG ratio of 0.98 and a beta of 0.91.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 8th. Investors of record on Friday, September 24th will be given a $0.11 dividend. The ex-dividend date of this dividend is Thursday, September 23rd. This represents a $0.44 annualized dividend and a yield of 0.74%. DENTSPLY SIRONA’s payout ratio is 24.58%.

Large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its stake in shares of DENTSPLY SIRONA by 61.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,798,974 shares of the medical instruments supplier’s stock valued at $1,008,133,000 after acquiring an additional 6,036,611 shares in the last quarter. Balyasny Asset Management LLC purchased a new position in shares of DENTSPLY SIRONA during the second quarter worth about $88,349,000. Marshall Wace North America L.P. grew its holdings in shares of DENTSPLY SIRONA by 103.7% during the second quarter. Marshall Wace North America L.P. now owns 2,463,633 shares of the medical instruments supplier’s stock worth $155,849,000 after purchasing an additional 1,253,906 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of DENTSPLY SIRONA by 13.3% during the first quarter. Janus Henderson Group PLC now owns 10,429,648 shares of the medical instruments supplier’s stock worth $665,516,000 after buying an additional 1,223,073 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in shares of DENTSPLY SIRONA by 6.8% during the first quarter. BlackRock Inc. now owns 17,073,574 shares of the medical instruments supplier’s stock worth $1,089,466,000 after buying an additional 1,089,635 shares during the last quarter. Institutional investors own 93.56% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona, Inc engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Technologies and Equipment and Consumables. The Technologies and Equipment segments comprises dental technology, equipment and healthcare consumable products such as dental implants, laboratory dental products, computer-aided design and computer-aided manufacturing systems, imaging systems, treatment centers and consumable medical device products.

See Also: What is a Call Option?

Get a free copy of the Zacks research report on DENTSPLY SIRONA (XRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.